Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)

Pierre Fenaux, MD, PhD, Aristotles Giagounidis, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam Mufti, MD, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Mario Cazzola, MD, Jay Backstrom, MD, Tommy Fu, PhD, Eva Hellström-Lindberg, MD, PhD

Blood (2010) 116 (21): 4027.

https://doi.org/10.1182/blood.V116.21.4027.4027

Published: 2010

Journal Articles

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Gudrun Göhring, MD, Aristoteles Giagounidis, Carlo Aul, Guntram Büsche, MD, Hans Kreipe, MD, Eva Hellström-Lindberg, MD, PhD, Robert D. Knight, MD, Brigitte Schlegelberger, MD

Blood (2008) 112 (11): 1647.

https://doi.org/10.1182/blood.V112.11.1647.1647

Published: 2008

Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD

Blood (2008) 112 (11): 1653.

https://doi.org/10.1182/blood.V112.11.1653.1653

Published: 2008

Journal Articles

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 227.

https://doi.org/10.1182/blood.V112.11.227.227

Published: 2008

Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD

Blood (2008) 112 (11): 3629.

https://doi.org/10.1182/blood.V112.11.3629.3629

Published: 2008

Journal Articles

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, Cristina Fernández-Santamaria, James S Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg, MD, PhD

Blood (2008) 112 (11): 5104.

https://doi.org/10.1182/blood.V112.11.5104.5104

Published: 2008

Journal Articles

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, Linda Zimmerman, BSN, David McKenzie, MS, C. L. Beach, PharmD, Lewis B. Silverman, MD

Blood (2008) 112 (11): 3636.

https://doi.org/10.1182/blood.V112.11.3636.3636

Published: 2008

Journal Articles

Gene Expression Profiling of Day 7 Erythroblasts from RARS Before and after Treatment with G-CSF.

Maryam Nikpour, MSc, Andrea Pellagatti, PhD, Martin Jädersten, MD, Ann-Mari Forsblom, James S. Wainscoat, MD, Jacqueline Boultwood, PhD, Eva Hellström-Lindberg, MD, PhD

Blood (2007) 110 (11): 2427.

https://doi.org/10.1182/blood.V110.11.2427.2427

Published: 2007

Journal Articles

Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.

Martin Jädersten, MD, Luca Malcovati, MD, Ingunn Dybedal, MD, Matteo Giovanni Della Porta, MD, Rosangela Invernizzi, MD, Scott M. Montgomery, PhD, Cristiana Pascutto, Anna Porwit-MacDonald, MD, Mario Cazzola, MD, Eva Hellström-Lindberg, MD, PhD

Blood (2006) 108 (11): 521.

https://doi.org/10.1182/blood.V108.11.521.521

Published: 2006

Journal Articles

A Distinct Molecular Signature of Purified Cancer Stem Cells: Evidence for a Hematopoietic Stem Cell Origin of the 5q- Syndrome.

Lars Nilsson, MD, PhD, Patrik Edén, PhD, Eleonor Olsson, Robert Månsson, Ingbritt Åstrand-Grundström, Bodil Strömbeck, Ramin Tehranchi, MD, PhD, Kim Theilgaard-Mönch, Robert Hast, MD, PhD, Eva Hellström-Lindberg, MD, PhD, Jan Samuelsson, MD, PhD, Gösta Bergh, MD, PhD, Bertil Johansson, MD, PhD, Mikael Sigvardsson, PhD, Åke Borg, PhD, Sten-Eirik W. Jacobsen, MD, PhD

Blood (2005) 106 (11): 4382.

https://doi.org/10.1182/blood.V106.11.4382.4382

Published: 2005

Journal Articles

Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion.

Martin Jädersten, MD, Andrea Pellagatti, Ann-Mari Forsblom, Emma K. Emanuelsson, Mats Merup, MD, Jan Samuelsson, MD, James S. Wainscoat, Jacqueline Boultwood, Eva Hellström-Lindberg, MD

Blood (2005) 106 (11): 3438.

https://doi.org/10.1182/blood.V106.11.3438.3438

Published: 2005

NARROW

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Gene Expression Profiling of Day 7 Erythroblasts from RARS Before and after Treatment with G-CSF.

Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.

A Distinct Molecular Signature of Purified Cancer Stem Cells: Evidence for a Hematopoietic Stem Cell Origin of the 5q- Syndrome.

Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only